Will QS report H1 2026 customer billings exceeding $15M?

Q1 delivered $11M — 73% of the $15M H1 threshold in one quarter. To miss, Q2 billings would need to be under $4M, well below the FY2025 implied quarterly run rate ($5M). With Eagle Line complete and initial cell production driving customer sampling, plus ecosystem billings from Murata/Corning now contributing, the probability of Q2 matching even a reduced pace is very high. The main downside tail is that Q1 ecosystem billings were one-time Cobra separator investments that don't recur, combined with lumpy VW milestone timing. Still a high-confidence YES.

The billings math strongly favors YES. $11M in Q1 + any reasonable Q2 (even half the FY2025 quarterly pace) clears $15M. However, the analyst/investor awareness that Q1 ecosystem billings may be front-loaded Cobra investments from Murata/Corning creates a genuine downside case where Q2 could be softer than expected. Management's vague 'up YoY' guidance does not specifically commit to Q2 strength. Still, the base case is Q2 $5-8M range, delivering H1 $16-19M.

Q1 2026's $11M billings is a decisive data point. The $15M H1 threshold was set with FY2025's $19.5M full-year baseline in mind. Q1 alone already exceeds two thirds of that target. For H1 to fall short, Q2 would have to show near-zero billings — inconsistent with management's unchanged guidance and with the operational momentum (Eagle Line complete, OEM engagement expanding). I assign 87% probability of YES, reserving 13% for unlikely but non-zero risks: billings lumpiness, VW milestone delays, ecosystem billings non-recurrence.

The Q1 $11M print effectively resolves this market. Q2 only needs $4M to clear $15M — less than the FY2025 implied quarterly run rate of $5M. Management reaffirmed billings 'up YoY' guidance with no indication of Q2 pullback. Multi-partner billings base reduces lumpiness risk. Very high probability YES.

Q1 $11M puts QS well on track to clear the $15M H1 threshold. The key risk is that ecosystem partner billings (Murata, Corning) tied to Cobra separator investments may be one-time rather than recurring. Even if ecosystem billings drop to zero in Q2 and VW billings halve (~$2M), Q2 totals $2M and H1 hits $13M — still short. However, that's an aggressively pessimistic scenario. Base case Q2 $5-7M, H1 $16-18M clears threshold. YES probability 84%.

Q1 $11M is impressive but QS billings have historically been lumpy and tied to development milestones. The jump from $5M quarterly pace to $11M suggests ecosystem billings front-loaded in Q1. A Q2 snapback to $3M is plausible if Cobra investments completed. However, even with aggressive deceleration, Q2 $4M+ is likely given baseline VW activity and continued sampling. YES probability 82%.

Q1 $11M gets QS to 73% of threshold already. Q2 needs only $4M. Given management's 'up YoY' guidance and multi-partner billings base, this is a high-probability YES.

Q1 billings of $11M is over half of FY2025 full year. Path to $15M H1 is clear with even modest Q2. Eagle Line complete and multi-OEM engagement supports continued activity.

Billings are lumpy but $11M in Q1 is a meaningful data point. High probability threshold clears. Reserve some probability for Q2 deceleration.